Voya Investment Management LLC Grows Holdings in Humana Inc. $HUM

Key Points

• Voya Investment Management LLC increased its stake in Humana Inc. by 7.7%, owning a total of 45,190 shares valued at approximately $11.96 million, as reported in their recent SEC filing.
• Several large investors such as Vanguard Group and Dodge & Cox also expanded their holdings in Humana during the first quarter, reflecting growing institutional interest in the company.
• Humana has recently declared a quarterly dividend of $0.885 per share, with an annualized dividend yield of 1.3%, set to be paid on October 31st.

Voya Investment Management LLC lifted its stake in shares of Humana Inc. (NYSE:HUM - Free Report) by 7.7% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 45,190 shares of the insurance provider's stock after acquiring an additional 3,221 shares during the period. Voya Investment Management LLC's holdings in Humana were worth $11,957,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of the stock. Vanguard Group Inc. lifted its holdings in shares of Humana by 8.9% during the 1st quarter. Vanguard Group Inc. now owns 13,972,872 shares of the insurance provider's stock worth $3,697,222,000 after acquiring an additional 1,143,662 shares during the period. Dodge & Cox lifted its holdings in shares of Humana by 5.5% during the 1st quarter. Dodge & Cox now owns 10,755,215 shares of the insurance provider's stock worth $2,845,830,000 after acquiring an additional 557,175 shares during the period. Pzena Investment Management LLC lifted its holdings in shares of Humana by 6.1% during the 1st quarter. Pzena Investment Management LLC now owns 3,828,923 shares of the insurance provider's stock worth $1,013,133,000 after acquiring an additional 219,541 shares during the period. Davis Selected Advisers lifted its holdings in shares of Humana by 3.3% during the 1st quarter. Davis Selected Advisers now owns 2,331,343 shares of the insurance provider's stock worth $616,873,000 after acquiring an additional 74,434 shares during the period. Finally, Hotchkis & Wiley Capital Management LLC lifted its holdings in shares of Humana by 1.6% during the 1st quarter. Hotchkis & Wiley Capital Management LLC now owns 1,236,936 shares of the insurance provider's stock worth $327,293,000 after acquiring an additional 19,613 shares during the period. 92.38% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research firms recently issued reports on HUM. Sanford C. Bernstein increased their target price on shares of Humana from $269.00 to $341.00 and gave the stock an "outperform" rating in a research report on Friday, September 5th. Royal Bank Of Canada increased their target price on shares of Humana from $283.00 to $322.00 and gave the stock an "outperform" rating in a research report on Thursday, August 21st. Robert W. Baird dropped their target price on shares of Humana from $300.00 to $297.00 and set a "neutral" rating for the company in a research report on Friday, July 25th. Truist Financial dropped their target price on shares of Humana from $280.00 to $260.00 and set a "hold" rating for the company in a research report on Wednesday, July 16th. Finally, Wall Street Zen downgraded shares of Humana from a "buy" rating to a "hold" rating in a research report on Saturday, August 2nd. Seven equities research analysts have rated the stock with a Buy rating and sixteen have given a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of "Hold" and a consensus price target of $289.24.

Humana Price Performance

NYSE:HUM opened at $272.04 on Wednesday. The business's 50-day moving average price is $266.79 and its 200 day moving average price is $257.30. The firm has a market cap of $32.72 billion, a P/E ratio of 20.88, a PEG ratio of 1.62 and a beta of 0.44. Humana Inc. has a 52-week low of $206.87 and a 52-week high of $324.38. The company has a quick ratio of 1.95, a current ratio of 1.95 and a debt-to-equity ratio of 0.69.

Humana (NYSE:HUM - Get Free Report) last issued its quarterly earnings results on Wednesday, July 30th. The insurance provider reported $6.27 earnings per share for the quarter, missing analysts' consensus estimates of $6.32 by ($0.05). The company had revenue of $32.39 billion during the quarter, compared to analysts' expectations of $31.85 billion. Humana had a return on equity of 13.67% and a net margin of 1.28%.The company's revenue for the quarter was up 9.6% compared to the same quarter last year. During the same period in the prior year, the business posted $6.96 EPS. Humana has set its FY 2025 guidance at 17.000- EPS. As a group, sell-side analysts predict that Humana Inc. will post 16.47 earnings per share for the current fiscal year.

Humana Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Friday, September 26th will be issued a dividend of $0.885 per share. This represents a $3.54 annualized dividend and a dividend yield of 1.3%. The ex-dividend date is Friday, September 26th. Humana's payout ratio is currently 27.17%.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc. (NYSE:HUM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.